SCHEMBL30193239

SCHEMBL30193239

C[C@H]1O[C@H](CC(N)=O)CC2=C1C(=O)c1c(O)cccc1C2=O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT3B Q9UBC3 1/20 0.82
HSP90AA1 P07900 1/20 0.82
PAX8 Q06710 1/20 0.82
AKT1 P31749 3/20 0.61
CTH P32929 1/20 0.61
TDP2 O95551 1/20 0.51
TCF4 P15884 1/20 0.48
CTNNB1 P35222 1/20 0.48
IDO1 P14902 4/20 0.44
STAT3 P40763 4/20 0.40
MAOA P21397 2/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
MAOB P27338 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nanaomycin SCHEMBL30778402 0.90 HSP90AA1 (1.00) DNMT3BHSP90AA1PAX8AKT1CTH
Nanaomycin SCHEMBL20473784 0.90 HSP90AA1 (1.00) DNMT3BHSP90AA1PAX8AKT1CTH
Nanaomycin SCHEMBL30861963 0.90 HSP90AA1 (1.00) DNMT3BHSP90AA1PAX8AKT1CTH
Nanaomycin SCHEMBL18567076 0.90 HSP90AA1 (1.00) DNMT3BHSP90AA1PAX8AKT1CTH
Nanafrocin SCHEMBL2111571 0.90 HSP90AA1 (1.00) DNMT3BHSP90AA1PAX8AKT1CTH
SCHEMBL29927569 0.87 DNMT3B (0.78) DNMT3BHSP90AA1PAX8AKT1CTH
SCHEMBL28398864 0.76 DNMT3B (0.77) DNMT3BHSP90AA1PAX8AKT1CTH
SCHEMBL20144857 0.76 DNMT3B (0.75) DNMT3BHSP90AA1PAX8AKT1CTH
SCHEMBL20442857 0.70 DNMT3B (0.66) DNMT3BHSP90AA1PAX8AKT1CTH
SCHEMBL1177648 0.70 DNMT3B (0.66) DNMT3BHSP90AA1PAX8AKT1CTH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109694-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC (US) 2026-04-23 US disclosed
US-12551555-B2 Compositions and methods for potentiating immune activity KUMQUAT BIOSCIENCES INC. (US) 2026-02-17 US disclosed
US-12503464-B2 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2025-12-23 US disclosed
US-20250304570-A1 BENZO-FUSED N-HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC (US) 2025-10-02 US disclosed
US-20250296927-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2025-09-25 US disclosed
US-20240398828-A1 HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-12-05 US disclosed
US-20240166641-A1 HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-05-23 US disclosed
US-20230092294-A1 COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE KUMQUAT BIOSCIENCES INC. 2023-03-23 US disclosed
US-20230044323-A1 COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY KUMQUAT BIOSCIENCES INC. 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092294-A1 COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE MYD88, NFATC1, ICOS DNMT3B 793/4885HSP90AA1 1636/4885PAX8 1121/4885
US-20260109694-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF CCR10, SLC11A2, MSR1 DNMT3B 4276/4885HSP90AA1 3511/4885PAX8 4714/4885
US-12551555-B2 Compositions and methods for potentiating immune activity PTPRCAP, PTPN2, PTPRC DNMT3B 1976/4885HSP90AA1 3576/4885PAX8 1757/4885
US-20230044323-A1 COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY NFATC1, MYD88, ICOS DNMT3B 710/4885HSP90AA1 1700/4885PAX8 909/4885
US-12503464-B2 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof BRCA1, STING1, IFNG DNMT3B 2913/4885HSP90AA1 653/4885PAX8 3526/4885
US-20240398828-A1 HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF CD74, HLA-DRB1, CD47 DNMT3B 2954/4885HSP90AA1 2735/4885PAX8 4038/4885
US-20250304570-A1 BENZO-FUSED N-HETEROCYCLES AND USES THEREOF NFATC1, BRCA1, MYD88 DNMT3B 4329/4885HSP90AA1 1138/4885PAX8 3394/4885
US-20250296927-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF MYD88, TP53, NFATC1 DNMT3B 4621/4885HSP90AA1 2695/4885PAX8 3909/4885
US-20240166641-A1 HETEROCYCLES AND USES THEREOF KRAS, HRAS, TP53 DNMT3B 4114/4885HSP90AA1 1487/4885PAX8 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.